Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Sep 21, 2026 · Filed Sep 23, 2026
The money chief of Amphstar Pharmaceuticals sold $103K of Amphstar Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$103,475
Shares × reported transaction price
46 days after results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $24.48 on Sep 21, 2026, 45% above its 52-week low and 17% below its high, after an 18% rise over the previous 30 trading days
52-week range $16.87 (May 15, 2026) to $29.40 (Jan 12, 2026), 61% of the way up, from 241 adjusted closes. 30 trading days earlier: $20.78 on Aug 7, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.5% | −0.4% | −3.1% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Amphstar Pharmaceuticals's SENIOR EVP, PRODUCTION CENTER sold $239K of Amphstar Pharmaceuticals shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.